IAM · Iambic Therapeutics
AI read · Good for IAM
The AI's read
The findings give Iambic early evidence that its drug candidates may work against tumors, including some resistant to existing drugs. IAM217 also has a letter allowing a Phase 1/2 study. The results are from preclinical models, not patients. IAM-C1's trial application is still expected in the fourth quarter of 2026, so neither candidate has yet shown benefits in people.